In vitro activities of peptide deformylase inhibitors against gram-positive pathogens.
作者信息
Wise R, Andrews J M, Ashby J
机构信息
Department of Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom.
出版信息
Antimicrob Agents Chemother. 2002 Apr;46(4):1117-8. doi: 10.1128/AAC.46.4.1117-1118.2002.
Abstract
The activities of six peptide deformylase (PDF) inhibitors against 107 respiratory tract pathogens were studied and compared to those of ciprofloxacin and amoxicillin-clavulanate. Against Streptococcus pneumoniae, BB-83698 and BB-83815 were the most active PDF inhibitors (MIC at which 90% of the organisms tested were inhibited [MIC(90)], 0.25 microg/ml). Five of the agents showed similar activity against Moraxella catarrhalis (MIC(90), 0.12 microg/ml). All PDF inhibitors were less active against Haemophilus influenzae; BB-3497 was the most active agent (MIC(90), 2 microg/ml). Five agents were studied against Chlamydia spp. and showed activity similar to that of ciprofloxacin (MIC, 0.5 to 4 microg/ml). This study demonstrates that PDF inhibitors have the potential to be developed for the treatment of respiratory tract infections.
摘要
相似文献
1
In vitro activities of peptide deformylase inhibitors against gram-positive pathogens.
Antimicrob Agents Chemother. 2002 Apr;46(4):1117-8. doi: 10.1128/AAC.46.4.1117-1118.2002.
2
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Antimicrob Agents Chemother. 2005 Apr;49(4):1468-76. doi: 10.1128/AAC.49.4.1468-1476.2005.
3
In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens.
Int J Antimicrob Agents. 2003 Dec;22(6):557-61. doi: 10.1016/s0924-8579(03)00246-2.
4
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.
J Med Chem. 2000 Jun 15;43(12):2324-31. doi: 10.1021/jm000018k.
5
Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.
Diagn Microbiol Infect Dis. 2004 May;49(1):63-5. doi: 10.1016/j.diagmicrobio.2003.12.005.
6
Peptide deformylase inhibitors with activity against respiratory tract pathogens.
Bioorg Med Chem Lett. 2004 Jan 5;14(1):59-62. doi: 10.1016/j.bmcl.2003.10.013.
7
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Clin Infect Dis. 2012 Sep;55 Suppl 3:S187-93. doi: 10.1093/cid/cis561.
8
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
J Antimicrob Chemother. 2006 May;57(5):914-23. doi: 10.1093/jac/dkl093. Epub 2006 Mar 20.
9
Structure-based design of a macrocyclic inhibitor for peptide deformylase.
J Med Chem. 2003 Aug 28;46(18):3771-4. doi: 10.1021/jm034113f.
10
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Diagn Microbiol Infect Dis. 2004 Jul;49(3):201-9. doi: 10.1016/j.diagmicrobio.2004.03.002.
引用本文的文献
1
Non-coding nucleotides and amino acids near the active site regulate peptide deformylase expression and inhibitor susceptibility in Chlamydia trachomatis.
Microbiology (Reading). 2011 Sep;157(Pt 9):2569-2581. doi: 10.1099/mic.0.049668-0. Epub 2011 Jun 30.
2
Drug forecast - the peptide deformylase inhibitors as antibacterial agents.
Ther Clin Risk Manag. 2007 Aug;3(4):513-25.
3
Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.
Antimicrob Agents Chemother. 2005 Aug;49(8):3129-35. doi: 10.1128/AAC.49.8.3129-3135.2005.
4
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Antimicrob Agents Chemother. 2005 Apr;49(4):1468-76. doi: 10.1128/AAC.49.4.1468-1476.2005.
5
Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.
Antimicrob Agents Chemother. 2004 Dec;48(12):4835-42. doi: 10.1128/AAC.48.12.4835-4842.2004.
6
An improved crystal form of Plasmodium falciparum peptide deformylase.
Protein Sci. 2004 Apr;13(4):1155-63. doi: 10.1110/ps.03456404. Epub 2004 Mar 9.
7
Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Antimicrob Agents Chemother. 2004 Jan;48(1):80-5. doi: 10.1128/AAC.48.1.80-85.2004.
8
In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 2003 Apr;47(4):1447-8. doi: 10.1128/AAC.47.4.1447-1448.2003.
本文引用的文献
1
Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.
Antimicrob Agents Chemother. 2001 Feb;45(2):563-70. doi: 10.1128/AAC.45.2.563-570.2001.
2
The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
J Antimicrob Chemother. 1999 Nov;44(5):679-88. doi: 10.1093/jac/44.5.679.
3
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis.
Eur J Clin Microbiol. 1987 Oct;6(5):587-9. doi: 10.1007/BF02014256.
Zotero 插件